ArticleFrontiers in nutrition2026
Astaxanthin alleviates altered hepatic lipid metabolism and oxidative stress in animals fed a high-sucrose diet.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of the present study was to analyze the effects of an Astaxanthin (ASTX)- rich extract-a powerful antioxidant-obtained from freshwater crustaceans ( Methods: Male Wistar rats were fed for 13 weeks with either: 1-a standard commercial rodent diet (RD), 2-a HSD, 3-a RD plus ASTX, or 4-a HSD plus ASTX. The rats were given orally either ASTX (10 mg/kg body weight/day in sunflower oil) or only the vehicle. Results: ASTX supplementation attenuated liver injury, as reflected by a reduction in steatosis severity and hepatic triglyceride accumulation. This effect appears to be primarily achieved by promoting mitochondrial fatty acid β-oxidation, as suggested by increased hepatic carnitine palmitoyltransferase-1 (CPT-1) activity, without significantly affecting lipogenesis. In addition, ASTX improved intracellular redox status by preventing the increase in hepatic reactive oxygen species (ROS) levels and by promoting a significant increase in the activity of the antioxidant enzymes catalase (CAT) and glutathione S-transferase (GST). ASTX was also able to restore altered GSH levels. Furthermore, ASTX induced an up-regulation of Nrf2 and a down-regulation of p-NFκB p65 protein expression, key transcription factors that govern cellular responses under pro-oxidant and pro-inflammatory conditions. Conclusion: This study suggests that ASTX obtained from the freshwater crustacean
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.